This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F10%3A6437%21RIV11-MZ0-00064165/
dctermshttp://purl.org/dc/terms/
n15http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n12http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n10http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n16http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n5http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F10%3A6437%21RIV11-MZ0-00064165
rdf:type
skos:Concept n12:Vysledek
dcterms:description
The study was designed to evaluate the long-term efficacy and safety of the 28-day prolonged-release Autogel formulation of the somatostatin analogue lanreotide (Lan-Autogel) in unselected patients with acromegaly. The study comprised four phases: washout; a double-blind comparison with placebo, at a single randomized dose (60, 90 or 120 mg) of Lan-Autogel; a single-blind, fixed-dose phase for four injections (placebo group was re-allocated to active treatment); and eight injections with doses tailored according to biochemical response. Serum samples were assessed for growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, at weeks 4, 13, 14, 15, 16, 32 and 52. 108 patients were enrolled and 99 completed 52 weeks' treatment. The study was designed to evaluate the long-term efficacy and safety of the 28-day prolonged-release Autogel formulation of the somatostatin analogue lanreotide (Lan-Autogel) in unselected patients with acromegaly. The study comprised four phases: washout; a double-blind comparison with placebo, at a single randomized dose (60, 90 or 120 mg) of Lan-Autogel; a single-blind, fixed-dose phase for four injections (placebo group was re-allocated to active treatment); and eight injections with doses tailored according to biochemical response. Serum samples were assessed for growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, at weeks 4, 13, 14, 15, 16, 32 and 52. 108 patients were enrolled and 99 completed 52 weeks' treatment.
dcterms:title
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
skos:prefLabel
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel(A (R)) therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
skos:notation
RIV/00064165:_____/10:6437!RIV11-MZ0-00064165
n3:aktivita
n9:V
n3:aktivity
V
n3:cisloPeriodika
1
n3:dodaniDat
n5:2011
n3:domaciTvurceVysledku
n15:9393110
n3:druhVysledku
n13:J
n3:duvernostUdaju
n10:S
n3:entitaPredkladatele
n6:predkladatel
n3:idSjednocenehoVysledku
283909
n3:idVysledku
RIV/00064165:_____/10:6437
n3:jazykVysledku
n16:eng
n3:klicovaSlova
Treatment of acromegaly; lanreotide Autogel therapy; insulin-like growth factor-1; growth hormone
n3:klicoveSlovo
n8:insulin-like%20growth%20factor-1 n8:growth%20hormone n8:lanreotide%20Autogel%20therapy n8:Treatment%20of%20acromegaly
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[EFE133E6236E]
n3:nazevZdroje
Pituitary
n3:obor
n14:FB
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
6
n3:rokUplatneniVysledku
n5:2010
n3:svazekPeriodika
13
n3:tvurceVysledku
Melmed, Shlomo Lam, Karen, S., L. Goth, Miklos, I. Schopohl, Jochen Cook, David Marek, Josef
n3:wos
000273685600003
s:issn
1386-341X
s:numberOfPages
11